USD
$0.00
(0.00%
)At Close (As of Oct 14, 2025)
$734.56B
Market Cap
53.2
P/E Ratio
15.27
EPS
$931.67
52 Week High
$622.41
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $37B |
Total Revenue | $45B |
Cost Of Revenue | $8.4B |
Costof Goods And Services Sold | $8.4B |
Operating Income | $18B |
Selling General And Administrative | $8.1B |
Research And Development | $11B |
Operating Expenses | $19B |
Investment Income Net | - |
Net Interest Income | -$605M |
Interest Income | $175M |
Interest Expense | $781M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $1.8B |
Income Before Tax | $13B |
Income Tax Expense | $2.1B |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $11B |
Comprehensive Income Net Of Tax | - |
Ebit | $13B |
Ebitda | $15B |
Net Income | $11B |
Field | Value (USD) |
---|---|
Total Assets | $79B |
Total Current Assets | $33B |
Cash And Cash Equivalents At Carrying Value | $3.3B |
Cash And Short Term Investments | $3.3B |
Inventory | $7.6B |
Current Net Receivables | $13B |
Total Non Current Assets | $46B |
Property Plant Equipment | $17B |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $6.2B |
Intangible Assets Excluding Goodwill | $6.2B |
Goodwill | $5.8B |
Investments | - |
Long Term Investments | $3.2B |
Short Term Investments | $155M |
Other Current Assets | $8.5B |
Other Non Current Assets | - |
Total Liabilities | $64B |
Total Current Liabilities | $28B |
Current Accounts Payable | $3.2B |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $5.1B |
Total Non Current Liabilities | $36B |
Capital Lease Obligations | - |
Long Term Debt | $29B |
Current Long Term Debt | $5.1B |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $34B |
Other Current Liabilities | $20B |
Other Non Current Liabilities | $2.2B |
Total Shareholder Equity | $14B |
Treasury Stock | - |
Retained Earnings | $14B |
Common Stock | $592M |
Common Stock Shares Outstanding | $904M |
Field | Value (USD) |
---|---|
Operating Cashflow | $8.8B |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $1.8B |
Capital Expenditures | $8.4B |
Change In Receivables | - |
Change In Inventory | -$2.5B |
Profit Loss | - |
Cashflow From Investment | -$9.3B |
Cashflow From Financing | $1.2B |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | $4.7B |
Dividend Payout Common Stock | $4.7B |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$2.5B |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $11B |
Field | Value (USD) |
---|---|
Gross Profit | $37B |
Total Revenue | $45B |
Cost Of Revenue | $8.4B |
Costof Goods And Services Sold | $8.4B |
Operating Income | $18B |
Selling General And Administrative | $8.1B |
Research And Development | $11B |
Operating Expenses | $19B |
Investment Income Net | - |
Net Interest Income | -$605M |
Interest Income | $175M |
Interest Expense | $781M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $1.8B |
Income Before Tax | $13B |
Income Tax Expense | $2.1B |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $11B |
Comprehensive Income Net Of Tax | - |
Ebit | $13B |
Ebitda | $15B |
Net Income | $11B |
Field | Value |
---|---|
Ex Dividend Date | 2025-08-15 |
Declaration Date | 2025-06-23 |
Record Date | 2025-08-15 |
Payment Date | 2025-09-10 |
Amount | 1.5 |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - GENERAL
Eli Lilly and Company (Ticker: LLY), headquartered in Indianapolis, Indiana, is a leading global pharmaceutical firm renowned for its innovation in the healthcare sector. With a diverse portfolio targeting critical therapeutic areas such as diabetes, oncology, and neurodegenerative diseases, Lilly markets its products in around 125 countries. The company emphasizes a commitment to advancing scientific knowledge and improving patient outcomes through its vigorous research and development initiatives. As a key player in the industry, Eli Lilly continues to pursue sustainable growth strategies and enhance shareholder value through a strong pipeline and strategic partnerships, solidifying its position as a cornerstone of modern medicine.